Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to NonSmall Cell Lung Cancer

Mandal, Bivash

doi:10.21007/etd.cghs.2015.0196

Cited by 3 publications

(2 citation statements)

References 332 publications

(509 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For ERL quantification, a reverse-phase HPLC chromatographic method on a NovaPak ® C18 column (3.9 × 150 mm) from Waters (Milford, MA, USA) was used, at a detection wavelength of 346 nm, as previously described [47]. Briefly, the same HPLC system was used but with an isocratic mobile phase consisting of acetonitrile and acidified water pH 2.6 (40:60, v/v) and a flow rate of 1.0 mL/min.…”

Section: Methodsmentioning

confidence: 99%

Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells

Santos-Rebelo

Kumar

Pillay

et al. 2019

Cancers

View full text Add to dashboard Cite

Pancreatic cancer is one of the most lethal cancers, with an extremely poor prognosis. The development of more effective therapies is thus imperative. Natural origin compounds isolated from Plectranthus genus, such as parvifloron D (PvD), have cytotoxic and antiproliferative activity against human tumour cells. However, PvD is a very low water-soluble compound, being nanotechnology a promising alternative strategy to solve this problem. Therefore, the aim of this study was to optimize a nanosystem for preferential delivery of PvD to pancreatic tumour cells. Albumin nanoparticles (BSA NPs) were produced through a desolvation method. Glucose cross-linking and bioactive functionalization profiles of BSA platform were elucidated and analysed using static lattice atomistic simulations in vacuum. Using the optimized methodology, PvD was encapsulated (yield higher than 80%) while NPs were characterized in terms of size (100–400 nm) and morphology. Importantly, to achieve a preferential targeting to pancreatic cancer cells, erlotinib and cetuximab were attached to the PvD-loaded nanoparticle surface, and their antiproliferative effects were evaluated in BxPC3 and Panc-1 cell lines. Erlotinib conjugated NPs presented the highest antiproliferative effect toward pancreatic tumour cells. Accordingly, cell cycle analysis of the BxPC3 cell line showed marked accumulation of tumour cells in G1-phase and cell cycle arrest promoted by NPs. As a result, erlotinib conjugated PvD-loaded BSA NPs must be considered a suitable and promising carrier to deliver PvD at the tumour site, improving the treatment of pancreatic cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells

Santos-Rebelo

Kumar

Pillay

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…In the release studies of the nanoparticulate systems containing ERLO, pH 3 acetate, pH 5.2 acetate, and pH 7.4 phosphate buffers were used as release media. 18,19 When the release studies in the literature were considered, the most meaningful results were obtained in a pH 3 acetate medium; therefore, the pH 3 acetate buffer release medium was selected. The volume of the receptor medium was 2.5 mL, and the sample volume added to the donor phase was 1.5 mL.…”

Section: Release Studies Using a Franz Diffusion Cellmentioning

confidence: 99%

Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen trometamol and Evaluation of In vitro Characteristic Properties

Çoban¹,

Değim²

2018

tjps

View full text Add to dashboard Cite

Erlotinib HCl bir tirozin kinaz reseptör inhibitörü olup, FDA tarafından ilk kez 2004 yılında küçük hücreli olmayan akciğer kanseri ile pankreas kanserinin tedavisi için onaylanmış olan antikanserojen bir etkin maddedir. Deksketoprofen trometamol ise NSAİİ'dir. Ancak günümüzde prostaglandinler üzerindeki inhibitör etkisinden dolayı karsinomada da etkili olduğu yapılan çalışmalar ile gösterilmektedir. Bu nedenle günümüzde ayrı ayrı ürünler halinde kullanılan deksketoprofen ve antikanserojen madde kombine edildiğinde, hem hastaya alım kolaylığı sağlayarak sabit bir kan düzeyi sağlanabileceği hem de kansere bağlı ağrı ile tümörün basınç nekrozu yaratma ve kanser prognozunu kötü yönde artırma etkisinin azaltılması ve tümörün etkin bir şekilde tedavisinin mümkün olabileceği düşünülmüştür. Nanokohleatlar ise üzerinde lipozomlar kadar çok fazla çalışmanın yapılmadığı ancak lipozomlara kıyasla daha fazla avantaja sahip olan ilaç taşıyıcı sistemlerdir. Gereç ve Yöntemler: Bu çalışmada, erlotinib HCl ve deksketoprofen trometamol çeşitli formülasyon çalışmaları ile nanokohleatlara yüklenmiş ve partikül büyüklüğü dağılımı, polidispersite indeksi ve zeta potansiyeli analizleri yapılmıştır. Elde edilen optimum formülasyon ile Franz difüzyon hücresinde salım çalışmaları ve geçirimli elektron mikroskobu görüntülemesi gerçekleştirilmiştir. Bulgular: Yapılan çalışmalar sonucunda partikül büyüklüğü 196.42-312.33 nm aralığında ve zeta potansiyeli 15 mV'den büyük olan taşıyıcı sistemler üretilmiştir. Esas etkin madde olan erlotinib HCl için en yüksek yükleme verimliliği ise %86.22±1.45 ile KOH-1B formülasyonunda elde edilmiştir. Sonuç: Çalışmalar sonucunda ilaçların nanokohleatlara başarılı bir şekilde yüklendiği ve yaklaşık %50 salım değerlerine ulaştığı tespit edilmiştir.

show abstract

Lipid-polymer hybrid nanoparticles in cancer therapy: current overview and future directions

2021

View full text Add to dashboard Cite

Cancer remains one of the leading cause of death worldwide. Current therapies are still ineffective in completely eradicating the disease. In the last two decades, the use of nanodelivery systems has emerged as an effective way to potentiate the therapeutic properties of anti-cancer drugs by improving their solubility and stability, prolong drug half-lives in plasma, minimize drug’s toxicity by reducing its off-target distribution, and promote drugs’ accumulation at the desired target site. Liposomes and polymer nanoparticles are the most studied and have demonstrated to be the most effective delivery systems for anti-cancer drugs. However, both liposomes and polymeric nanoparticles suffer from limitations, including high instability, rapid drug release, limited drug loading capacity, low biocompatibility and lack of suitability for large-scale production. To overcome these limitations, lipid-polymer hybrid nanoparticles (LPHNPs) have been developed to merge the advantages of both lipid- and polymer-based nanocarriers, such as high biocompatibility and stability, improved drug loading and controlled release, as well as increased drug half-lives and therapeutic efficacy. This review provides an overview on the synthesis, properties and application of LPHNPs for cancer therapy.

show abstract

Design, Development and Evaluation of Erlotinib-Loaded Hybrid Nanoparticles for Targeted Drug Delivery to NonSmall Cell Lung Cancer

Cited by 3 publications

References 332 publications

Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells

Development and Mechanistic Insight into the Enhanced Cytotoxic Potential of Parvifloron D Albumin Nanoparticles in EGFR-Overexpressing Pancreatic Cancer Cells

Development of Nanocochleates Containing Erlotinib HCl and Dexketoprofen trometamol and Evaluation of In vitro Characteristic Properties

Lipid-polymer hybrid nanoparticles in cancer therapy: current overview and future directions

Contact Info

Product

Resources

About